To the Editor:
We would like to share ideas on the report “Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials”1. Balevic noted that “well-designed clinical trials that include patients with rheumatic disease are urgently needed to characterize the efficacy, safety, and target exposures for hydroxychloroquine1.” The effect of hydroxychloroquine (HCQ) against the coronavirus disease 2019 (COVID-19) is an interesting issue in clinical rheumatology. In a recent publication, the observation of an extremely …
Address correspondence to B. Joob, Private Academic Consultant, Sanitation1 Medical Academic Center, Bangkok, Thailand. Email: beuyjoob{at}hotmail.com.